{"ticker": {"uuid": "a19fea38-1ef7-45fd-bd1e-d50a43870858", "symbol": "ANIK", "name": "Anika Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Anika Therapeutics to issue Q2FY26 results on July 29", "summary": "Anika Therapeutics, Inc. (NASDAQ: ANIK) is set to release its Q2FY26 financial results before the market opens on Wednesday, July 29, 2026. The company will host a conference call at 8:30 a.m. ET to discuss the results and provide business highlights. Investors can access the cal", "url": "https://scanx.trade/stock-market-news/companies/anika-therapeutics-to-issue-q2fy26-results-on-july-29/45701561", "source_name": "scanx.trade", "published_at": "2026-07-15T22:45:41", "published_display": "15 Jul 2026 22:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026", "summary": "Anika Therapeutics, Inc. (NASDAQ: ANIK) announced it will release its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. A conference call will follow at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the live ", "url": "https://www.globenewswire.com/news-release/2026/07/15/3328087/28467/en/Anika-to-Issue-Second-Quarter-2026-Financial-Results-on-Wednesday-July-29-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T19:45:41", "published_display": "15 Jul 2026 19:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika sets July 29 conference call for second-quarter results", "summary": "Anika Therapeutics, Inc. (NASDAQ: ANIK) announced it will release its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. Following the release, management will host a conference call at 8:30 a.m. ET to discuss the results and business highlights", "url": "https://www.stocktitan.net/news/ANIK/anika-to-issue-second-quarter-2026-financial-results-on-wednesday-dhpg92q45c6y.html", "source_name": "Stock Titan", "published_at": "2026-07-15T19:45:41", "published_display": "15 Jul 2026 19:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Expands Revolving Credit Facility Agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPSUZyd2lERVB5b3VUV1Z0cXF2Q3FyNFlVamtjLTYyU1l6WXhpdjlFQlRySHJEeE84OFRKcU5zSXd2Yl9VZ1RKTkRtZDcxX0djZ0V2ZUJWZ2xsWHFjVFdKSlF1RnpxNW9CZHZzZW5xa0lKeW1XMm9sTzJtRnJ4S2pPclNBTmt1TUl2MUlNWXRlb1F2SU8xVHJReUdmZmdMejc4SFFJQkZBSkZvRjJFbXBRR0Q5a2o?oc=5", "source_name": "TipRanks", "published_at": "2026-07-15T07:41:42+00:00", "published_display": "15 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Extends $50M Revolver to 2031 With Bank of America; Upsize Option to $100M", "summary": "Anika Therapeutics has extended its senior secured revolving credit facility with Bank of America to July 10, 2031, providing $50 million in commitments with an option to increase to $100 million. The agreement aims to enhance the company's liquidity and financial flexibility for", "url": "https://www.tradingview.com/news/tradingview:52e6ece812cc4:0-anika-therapeutics-extends-50m-revolver-to-2031-with-bank-of-america-upsize-option-to-100m/", "source_name": "TradingView", "published_at": "2026-07-14T20:40:58", "published_display": "14 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Enters Fifth Amendment To Credit Agreement - SEC Filing", "summary": "Anika Therapeutics has announced that it has entered into a Fifth Amendment to its Credit Agreement. This information was disclosed in a recent SEC filing. The news was reported by Reuters.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN43G0ZL:0-anika-therapeutics-enters-fifth-amendment-to-credit-agreement-sec-filing/", "source_name": "TradingView", "published_at": "2026-07-14T20:40:58", "published_display": "14 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics (NASDAQ: ANIK) updates $50M revolving credit line terms", "summary": "Anika Therapeutics (NASDAQ: ANIK) has updated the terms of its $50 million revolving credit line with Bank of America, N.A. through a Fifth Amendment to its Credit Agreement, extending the maturity date to July 10, 2031. The amended agreement allows for an additional $50 million ", "url": "https://www.stocktitan.net/sec-filings/ANIK/8-k-anika-therapeutics-inc-reports-material-event-e1537c27dc04.html", "source_name": "Stock Titan", "published_at": "2026-07-14T20:40:58", "published_display": "14 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Anika Therapeutics Inc. \u2013 NASDAQ:ANIK", "summary": "This article focuses on the \"Price to book forward\" metric for Anika Therapeutics Inc. (NASDAQ: ANIK). It presents financial data for the company across different periods, including value, change, and percentage change. The content appears to be a basic financial data display fro", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIK/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T08:11:24", "published_display": "05 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Edges Higher Amid Consolidation: ANIK Stock Tests Key Resistance - PCR Moving Average", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNakw0eHh0RVpiN1dvTkM4Z3Zndmlmc29Jc0dtX19CRW50NTYydGFNcE41UDl3ZzlzNzZmLXY4eDA5UUUyUnVJMFIyblQ0bFlZbWY5QnItUHRmdkRocnAzWDJkSXp2ZGhJSU9xMDduNmZsLWRCb2Fjc3JYTGZRUDNIdGQ4LURlRUpGZGtlUFZ4UnZ0MWtRVUlSbU5DY0s5M2kyZ0xraThNbzBadG5EQ01fX01hQ2ZaZlhqaGJFNFlUcEwybnlTalE5TzZubw?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics extends implant lifespan with engineered Hyaff for regenerative medicine", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNVFg3Q01DT3plNm0zMHRrdXFSeWxkRHZLMzBabkZsLThZRVUxdmFpMWUxMVl5aFVfMkZZdS1iRWEwTkZWZzdqMERDbFVKa1k5cmlGN19DdkZjVU1iOWVoaW5GcW9nU1VOZDRrUWxMb2dvV3V3cVNoQlVhbzJmUHgtNU1n?oc=5", "source_name": "Traders Union", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics, Inc.(NasdaqGS: ANIK) dropped from Russell 2000 Defensive Index", "summary": "Anika Therapeutics, Inc. (NasdaqGS: ANIK) has been removed from the Russell 2000 Defensive Index, as reported on June 28, 2026. This news comes amidst other recent updates for the company, including its Q1 2026 earnings report, maintained earnings guidance for fiscal year 2026, a", "url": "https://www.marketscreener.com/news/anika-therapeutics-inc-nasdaqgs-anik-dropped-from-russell-2000-defensive-index-ce7f5fddd88df522", "source_name": "marketscreener.com", "published_at": "2026-06-29T21:09:03", "published_display": "29 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics, Inc. Actuals & Estimates (NASDAQ:ANIK)", "summary": "This article provides an overview of Anika Therapeutics, Inc. (NASDAQ:ANIK) stock performance, financial actuals, and analyst estimates. It covers details like current stock price, historical highs and lows, market capitalization, earnings reports, revenue, net income, and upcomi", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIK/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:40:18", "published_display": "26 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANIK Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Anika Therapeutics Inc. (ANIK) stock performance, analyst forecasts, and various financial metrics. It includes the current stock price, historical highs and lows, analyst price targets, and details on recent earnings and revenue. The informat", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIK/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T15:11:57", "published_display": "25 Jun 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Anika Therapeutics (ANIK) receives 10,402 RSU award, holding 58,273 shares", "summary": "Anika Therapeutics director Richard Stephen was granted 10,402 restricted stock units (RSUs) on June 18, 2026. These RSUs vest in full by the earlier of the 2027 annual shareholder meeting or June 18, 2027. Following this award, Richard Stephen directly holds 58,273 shares of Ani", "url": "https://www.stocktitan.net/sec-filings/ANIK/form-4-anika-therapeutics-inc-insider-trading-activity-dfb922a5805b.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:40:20", "published_display": "23 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Anika Therapeutics (ANIK) receives 10,402 RSUs equity grant", "summary": "Anika Therapeutics director Joseph H. Capper received an equity grant of 10,402 Restricted Stock Units (RSUs) on June 18, 2026, increasing his direct holdings to 30,805 shares. These RSUs, granted at no cash cost, will vest in full on the earlier of the company's 2027 annual stoc", "url": "https://www.stocktitan.net/sec-filings/ANIK/form-4-anika-therapeutics-inc-insider-trading-activity-9f03c92f2277.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:39:32", "published_display": "23 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics increases equity plan shares under amended omnibus and ESPP", "summary": "Anika Therapeutics' board has approved amendments to its 2017 Omnibus Incentive Plan and 2021 Employee Stock Purchase Plan (ESPP), which will increase share reserves, pending stockholder approval at the 2026 Annual Meeting. The 2017 Plan will reserve an additional 350,000 shares,", "url": "https://www.tradingview.com/news/tradingview:9b0dc9415ef36:0-anika-therapeutics-increases-equity-plan-shares-under-amended-omnibus-and-espp/", "source_name": "TradingView", "published_at": "2026-06-23T20:39:31", "published_display": "23 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Anika Therapeutics, Inc. Insider Trading Activity", "summary": "Anika Therapeutics director Sheryl L. Conley reported an acquisition of 10,402 restricted stock units (RSUs) of common stock as an equity award in a Form 4 filing. These RSUs vest fully on the earlier of the company's 2027 annual stockholder meeting or June 18, 2027. Following th", "url": "https://www.stocktitan.net/sec-filings/ANIK/form-4-anika-therapeutics-inc-insider-trading-activity-698a561bccc7.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:39:31", "published_display": "23 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics (NASDAQ: ANIK) shareholders back equity plans and director slate", "summary": "Anika Therapeutics shareholders approved changes to its equity compensation plans and elected three Class III directors at its 2026 Annual Meeting. The approved revisions include increasing the common stock reserved under the omnibus incentive plan by 350,000 shares and doubling ", "url": "https://www.stocktitan.net/sec-filings/ANIK/8-k-anika-therapeutics-inc-reports-material-event-b917cfa932eb.html", "source_name": "Stock Titan", "published_at": "2026-06-23T19:39:31", "published_display": "23 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Anika Therapeutics (NASDAQ: ANIK) receives 10,402 RSU grant", "summary": "Anika Therapeutics director Gary P. Fischetti was granted 10,402 restricted stock units (RSUs), increasing his direct holdings to 52,015 shares. The RSUs, valued at $0.00 per share, encourage long-term alignment with shareholder interests by vesting fully on the earlier of the co", "url": "https://www.stocktitan.net/sec-filings/ANIK/form-4-anika-therapeutics-inc-insider-trading-activity-7f1b19f21bf5.html", "source_name": "Stock Titan", "published_at": "2026-06-21T10:11:24", "published_display": "21 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Inc (ANIK) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Anika Therapeutics Inc (ANIK) currently holds a strong financial score of 7.95, placing it 52nd out of 203 in the Healthcare Equipment & Supplies industry. The company reported a 13.16% year-over-year increase in its latest quarterly revenue, reaching $29.61M, and a net profit in", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anik/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T04:39:54", "published_display": "18 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Inc (ANIK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Anika Therapeutics Inc (ANIK) based on its business segments and geographical regions. As of April 6, 2024, the company's revenue is primarily driven by its OEM Channel (57.09%) and Commercial Channel (42.91%). Geographically", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anik/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:08:57", "published_display": "17 Jun 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Inc (ANIK) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Anika Therapeutics Inc's (ANIK) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and indicates no historical data for stock splits. The page also presents current stock pe", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anik/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T19:08:57", "published_display": "17 Jun 2026 19:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Inc (ANIK) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis of Anika Therapeutics Inc (ANIK), noting its current valuation score of 8.58, ranking it 83 out of 203 in the Healthcare Equipment & Supplies industry. It highlights the company's P/E ratio of -18.06, which is significantly below its rece", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anik/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T10:40:20", "published_display": "17 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Inc (ANIK) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Anika Therapeutics Inc (ANIK), detailing its current price momentum, support and resistance levels, and indicator readings. The analysis covers various technical indicators like MACD, RSI, and moving averages (MA5 to MA200), concludin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anik/technical", "source_name": "TradingKey", "published_at": "2026-06-17T10:40:20", "published_display": "17 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Inc (ANIK) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Anika Therapeutics Inc (ANIK) currently has an earnings forecast score of 9.00, placing it 4th in the Healthcare Equipment & Supplies industry. Analysts have a consensus \"Strong Buy\" rating for ANIK, with an average price target of $16.00. The company's expected revenue for the n", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anik/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T10:40:20", "published_display": "17 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(ANIK) Movement Within Algorithmic Entry Frameworks", "summary": "The article analyzes Anika Therapeutics Inc. (NASDAQ: ANIK) through algorithmic entry frameworks, identifying a strong near-term sentiment with a long-term positive bias. It highlights an exceptional 58.3:1 risk-reward setup targeting a 16.6% gain and provides three institutional", "url": "https://news.stocktradersdaily.com/news_release/10/ANIK_Movement_Within_Algorithmic_Entry_Frameworks_061326061402_1781388842.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-13T18:14:00", "published_display": "13 Jun 2026 18:14", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Griffin Stephen D.", "summary": "This document is a statement of changes in beneficial ownership of securities for Officer Griffin Stephen D. at Anika Therapeutics. It is filed as a Form 4, indicating a mandatory disclosure of transactions by company insiders.", "url": "https://www.moomoo.com/news/notice/307479012/anika-therapeutics-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-13T13:10:18", "published_display": "13 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics (ANIK) Edges Higher as Shares Test Key Resistance Levels - Key Reversal Day", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQVWpfdEQxZmNfdkplaXBjbkkzd0NmQ0dZZjNIdXpBbENMY0daSjFBcU9GaldUZEtLVXBIc1MtSWpneVFrazFjUU1ud1phYTRoc3NxYnVpa3ZudTJqdEstN2cyUnI1Nk8tNEJLU0Q1aW14WjNFbGUxTWdwZU82NzlRNWg4UnJ4S2pkS2FRY1RqRG1iVncteHp0Q0NJeG5SVlY1OEFNX0JmRTFGZHVFNHA3cUl5NUF5S2F2QWI2UmFfcHE?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Anika Therapeutics Inc. announced inducement grants of restricted stock units (RSUs) to a newly hired non-executive employee on June 1, 2026. The grant, covering 3,360 shares, was made under the company's 2021 Inducement Plan and was approved by the compensation committee in acco", "url": "https://finance.yahoo.com/markets/stocks/articles/anika-reports-inducement-grants-under-210000086.html", "source_name": "Market source", "published_at": "2026-06-08T11:40:11", "published_display": "08 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika reports inducement grants", "summary": "Anika Therapeutics, Inc. announced that it granted restricted stock units (RSUs) covering 3,360 shares of common stock to a newly hired non-executive employee on June 1, 2026. This grant was made under the company's 2021 Inducement Plan and was approved by the compensation commit", "url": "https://medicalbuyer.co.in/anika-reports-inducement-grants-3/", "source_name": "Medical Buyer", "published_at": "2026-06-08T11:09:47", "published_display": "08 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics grants 3,360 RSUs to new employee as inducement under Nasdaq rules.", "summary": "Anika Therapeutics has granted 3,360 restricted stock units (RSUs) to a new non-executive employee. This grant, made on June 1, 2026, serves as an inducement for employment under Nasdaq rules and will vest in equal installments over three years, dependent on continuous service. T", "url": "https://pluang.com/en/news-feed/anika-laporkan-pemberian-saham-terbatas-untuk-karyawan-baru", "source_name": "Pluang", "published_at": "2026-06-05T21:09:43", "published_display": "05 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Anika hire receives 3,360 stock units as job inducement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNMzhrMDJuTUUwZHllQkJiZjNWTjdaRHdRLVRPQlUtTEViYXpyVmhYX0Q2YWp6NWtiTGcwN3FDWVdVMU9yVGRsY3V4dXJTTkdaTDIyWlJVZVBCYk9Iamh4WHlRY2FjYVJyb3J4NE4xRzZ4R21YNWJISklEaW4tMDduSlkzemVXWEMwUnVMNFpKbklaNkVub2FQTV9mZTRQcW9VX0RORkNlR1M3VFZrejYzbFlxOUZuUU5sLUs0?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics (ANIK) Hovers Near Support With Minimal Price Movement - Resistance Breakout Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQM1o4SVpvS2hqd251b1p6VklIU1ZBd3BVSjkyamFPTjhsWVhHazUtTXBBbDFPRTBpbVMwNVNleHRGUmhhQzM4WDh0SGJWYjFWSXowX0o0V3lUYkZUNUUxSFYzTFlhUFF0TTh3RWh3OHlOWnlMQWpualczUEN4ZWd1NHowNFhfZGhmeWtnT1hiWHR3WFpHcGlMQ2c0MHh2Wkl2R0RyaS1ZTmhXRi1SeXRFQkFXUnREZEdhYi1n?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "President of Anika Therapeutics Picks Up 51% More Stock", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/president-anika-therapeutics-picks-51-133628327.html", "source_name": "Simply Wall St.", "published_at": "2026-05-03T13:36:28+00:00", "published_display": "03 May 2026 13:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics (ANIK) Q4 Profit Challenges Ongoing Unprofitability Narrative Ahead Of Q1 Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bullish On Anika Therapeutics\u2019s Pullback As Integrity Scales (NASDAQ:ANIK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQUkJOUk5JaTUtcjZ4SUdYY0tONDkxMUU2QVVUNnhmVE5nTC03enpCbnd5QURuVVpQREZRUzVGQ0xQbVRJdHZBeU1XMVlsOThaNVlNV1FId3lBN0c3VDVMeXRPSi1XZjlUQzNmQXV1YW9qdDFXbnNab1F5YzI5TkM2UDFWNG5FdVhWYjF1bHYtcXhTUC1wSUttWVFESkpwcWtjemc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/58d88200-1129-3efb-806a-65aac008518e/anika-therapeutics-q1.html", "source_name": "MarketBeat", "published_at": "2026-04-29T14:20:26+00:00", "published_display": "29 Apr 2026 14:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/anika-q1-earnings-snapshot-111451597.html", "source_name": "Associated Press", "published_at": "2026-04-29T11:14:51+00:00", "published_display": "29 Apr 2026 11:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/anika-reports-first-quarter-2026-110500399.html", "source_name": "GlobeNewswire", "published_at": "2026-04-29T11:05:00+00:00", "published_display": "29 Apr 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPeU5mR250NHZjRnFZT3pGaGc4eTN3SGRZUnpPeFFMM3B5cWVSa29WQnRyMFMtS1FLVXAzV0FKeUFsQ05NX0Nnbkswbjk5V2ZRNTQ4ZU14R1Q5bF9XaVJubER4OFpPQmpzRGNzclQ3MjVaS0tJenJIcWdoTVd4ZENtbXNOMFZpQUs3dWNWdjdyZUdwdU1uM2tRTVVJUW9lWE5S?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOeElqTzdGRGVmTUxTYmlueVl6MmM2eE5WUU44OHdsMUozekJzNDdCWGxlUnBQZ2JNYVhuTl91T3RjbHBLQWZST1M5YTctUUZDQzhKd0JnWHBvWE83b2dzZS1peHNzc1didDFZcmIzdDNFSDU4N3V4dVpYLUZJRnBGQTU3LTlQb2MtT0dZSzkwZ05ocTBzMTFmOFBORGdNSjZYS2Q1eVJqcHRhNGNCXzY0OTZnb01lb0pIeUlITXVvaWt3Z2tJd0JWUVF4YUNYRkNUYnZDUWRJNHUtRm9XeUZ1RGxKa04?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Anika employee gets 3,138 stock units vesting over 3 years", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQcVp2OXRXVHdYMk54dUNpU21JRGY3M2R3dzlIUU53ZllWcXpHNjRkdnVuNUdxWkpuLUF6R0lLLTZyZlUwdUpYR09SemIxMXpKX2tYWkE3N0FjUVFUZnJ0X0lpME1PYi1sTmtBdlAwdnA2NUh4NDRJZDVVaHV6WUNIN2RHcHRKWXVvbFpzaUxZbXNfM2RaUFNhQnFKZHk1cGxqU1ozcmlSQTk4YnBaYzZCdkpycmZ4SDhpZmw4?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANIKA THERAPEUTICS ($ANIK) Releases Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPRXpLY21sSWx5b2t2b09HYllxWXM2cnVlZnlwX2Q1NFU0U1RMT2kxWE1iQ3pBcHdrR3dtakZ2cWZTejlKdnUxOWhlcDFERkxLY3ZlSmtabm9ZUHA1THVMcFhNV3pBWERrdFcwVDlGTHdfdTZVVUtwWHlsQ1VFanVlU2JoV09rUl9GUzJjQzln?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C.", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Osteoarthritis Therapeutics Market Size, Share | Growth [2034]", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQTGhscWV3bkFLYUFRZEJlV28wSEY2SlRCNVlZWlVHMTZXTzBaUEh0QUFhaEJRWkp5bGU5WGZ2cVduRG96MFpZWDM5V184ejlxZjlTRUVvZHpVZndraUd3NHFwV0FuYXRUQTBwd2hHUnIyU3hDVFUyOFVNVUVLNEFGSU5oRE9UX3lP?oc=5", "source_name": "Fortune Business Insights", "published_at": "2026-01-21T09:41:42+00:00", "published_display": "21 Jan 2026 09:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics (ANIK) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5MNUpteXpnQ2QyOE1qYTh1MEVDUU5WYlJLZ0JXS3JWUm1QbXVOeFFrcVVlOWNIS1VtRE5HU0FiSGNQd1V4YXhuRjRSWjNjUmVxZFNZ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:25:10+00:00", "published_display": "25 Apr 2025 00:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Anika Therapeutics to issue Q2FY26 results on July 29", "summary": "Anika Therapeutics, Inc. (NASDAQ: ANIK) is set to release its Q2FY26 financial results before the market opens on Wednesday, July 29, 2026. The company will host a conference call at 8:30 a.m. ET to discuss the results and provide business highlights. Investors can access the cal", "url": "https://scanx.trade/stock-market-news/companies/anika-therapeutics-to-issue-q2fy26-results-on-july-29/45701561", "source_name": "scanx.trade", "published_at": "2026-07-15T22:45:41", "published_display": "15 Jul 2026 22:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026", "summary": "Anika Therapeutics, Inc. (NASDAQ: ANIK) announced it will release its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. A conference call will follow at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the live ", "url": "https://www.globenewswire.com/news-release/2026/07/15/3328087/28467/en/Anika-to-Issue-Second-Quarter-2026-Financial-Results-on-Wednesday-July-29-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T19:45:41", "published_display": "15 Jul 2026 19:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika sets July 29 conference call for second-quarter results", "summary": "Anika Therapeutics, Inc. (NASDAQ: ANIK) announced it will release its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. Following the release, management will host a conference call at 8:30 a.m. ET to discuss the results and business highlights", "url": "https://www.stocktitan.net/news/ANIK/anika-to-issue-second-quarter-2026-financial-results-on-wednesday-dhpg92q45c6y.html", "source_name": "Stock Titan", "published_at": "2026-07-15T19:45:41", "published_display": "15 Jul 2026 19:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Expands Revolving Credit Facility Agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPSUZyd2lERVB5b3VUV1Z0cXF2Q3FyNFlVamtjLTYyU1l6WXhpdjlFQlRySHJEeE84OFRKcU5zSXd2Yl9VZ1RKTkRtZDcxX0djZ0V2ZUJWZ2xsWHFjVFdKSlF1RnpxNW9CZHZzZW5xa0lKeW1XMm9sTzJtRnJ4S2pPclNBTmt1TUl2MUlNWXRlb1F2SU8xVHJReUdmZmdMejc4SFFJQkZBSkZvRjJFbXBRR0Q5a2o?oc=5", "source_name": "TipRanks", "published_at": "2026-07-15T07:41:42+00:00", "published_display": "15 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Extends $50M Revolver to 2031 With Bank of America; Upsize Option to $100M", "summary": "Anika Therapeutics has extended its senior secured revolving credit facility with Bank of America to July 10, 2031, providing $50 million in commitments with an option to increase to $100 million. The agreement aims to enhance the company's liquidity and financial flexibility for", "url": "https://www.tradingview.com/news/tradingview:52e6ece812cc4:0-anika-therapeutics-extends-50m-revolver-to-2031-with-bank-of-america-upsize-option-to-100m/", "source_name": "TradingView", "published_at": "2026-07-14T20:40:58", "published_display": "14 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Enters Fifth Amendment To Credit Agreement - SEC Filing", "summary": "Anika Therapeutics has announced that it has entered into a Fifth Amendment to its Credit Agreement. This information was disclosed in a recent SEC filing. The news was reported by Reuters.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN43G0ZL:0-anika-therapeutics-enters-fifth-amendment-to-credit-agreement-sec-filing/", "source_name": "TradingView", "published_at": "2026-07-14T20:40:58", "published_display": "14 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics (NASDAQ: ANIK) updates $50M revolving credit line terms", "summary": "Anika Therapeutics (NASDAQ: ANIK) has updated the terms of its $50 million revolving credit line with Bank of America, N.A. through a Fifth Amendment to its Credit Agreement, extending the maturity date to July 10, 2031. The amended agreement allows for an additional $50 million ", "url": "https://www.stocktitan.net/sec-filings/ANIK/8-k-anika-therapeutics-inc-reports-material-event-e1537c27dc04.html", "source_name": "Stock Titan", "published_at": "2026-07-14T20:40:58", "published_display": "14 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Anika Therapeutics Inc. \u2013 NASDAQ:ANIK", "summary": "This article focuses on the \"Price to book forward\" metric for Anika Therapeutics Inc. (NASDAQ: ANIK). It presents financial data for the company across different periods, including value, change, and percentage change. The content appears to be a basic financial data display fro", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIK/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T08:11:24", "published_display": "05 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Edges Higher Amid Consolidation: ANIK Stock Tests Key Resistance - PCR Moving Average", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNakw0eHh0RVpiN1dvTkM4Z3Zndmlmc29Jc0dtX19CRW50NTYydGFNcE41UDl3ZzlzNzZmLXY4eDA5UUUyUnVJMFIyblQ0bFlZbWY5QnItUHRmdkRocnAzWDJkSXp2ZGhJSU9xMDduNmZsLWRCb2Fjc3JYTGZRUDNIdGQ4LURlRUpGZGtlUFZ4UnZ0MWtRVUlSbU5DY0s5M2kyZ0xraThNbzBadG5EQ01fX01hQ2ZaZlhqaGJFNFlUcEwybnlTalE5TzZubw?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics extends implant lifespan with engineered Hyaff for regenerative medicine", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNVFg3Q01DT3plNm0zMHRrdXFSeWxkRHZLMzBabkZsLThZRVUxdmFpMWUxMVl5aFVfMkZZdS1iRWEwTkZWZzdqMERDbFVKa1k5cmlGN19DdkZjVU1iOWVoaW5GcW9nU1VOZDRrUWxMb2dvV3V3cVNoQlVhbzJmUHgtNU1n?oc=5", "source_name": "Traders Union", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics, Inc.(NasdaqGS: ANIK) dropped from Russell 2000 Defensive Index", "summary": "Anika Therapeutics, Inc. (NasdaqGS: ANIK) has been removed from the Russell 2000 Defensive Index, as reported on June 28, 2026. This news comes amidst other recent updates for the company, including its Q1 2026 earnings report, maintained earnings guidance for fiscal year 2026, a", "url": "https://www.marketscreener.com/news/anika-therapeutics-inc-nasdaqgs-anik-dropped-from-russell-2000-defensive-index-ce7f5fddd88df522", "source_name": "marketscreener.com", "published_at": "2026-06-29T21:09:03", "published_display": "29 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics, Inc. Actuals & Estimates (NASDAQ:ANIK)", "summary": "This article provides an overview of Anika Therapeutics, Inc. (NASDAQ:ANIK) stock performance, financial actuals, and analyst estimates. It covers details like current stock price, historical highs and lows, market capitalization, earnings reports, revenue, net income, and upcomi", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIK/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:40:18", "published_display": "26 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANIK Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Anika Therapeutics Inc. (ANIK) stock performance, analyst forecasts, and various financial metrics. It includes the current stock price, historical highs and lows, analyst price targets, and details on recent earnings and revenue. The informat", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIK/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T15:11:57", "published_display": "25 Jun 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Anika Therapeutics (ANIK) receives 10,402 RSU award, holding 58,273 shares", "summary": "Anika Therapeutics director Richard Stephen was granted 10,402 restricted stock units (RSUs) on June 18, 2026. These RSUs vest in full by the earlier of the 2027 annual shareholder meeting or June 18, 2027. Following this award, Richard Stephen directly holds 58,273 shares of Ani", "url": "https://www.stocktitan.net/sec-filings/ANIK/form-4-anika-therapeutics-inc-insider-trading-activity-dfb922a5805b.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:40:20", "published_display": "23 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Anika Therapeutics (ANIK) receives 10,402 RSUs equity grant", "summary": "Anika Therapeutics director Joseph H. Capper received an equity grant of 10,402 Restricted Stock Units (RSUs) on June 18, 2026, increasing his direct holdings to 30,805 shares. These RSUs, granted at no cash cost, will vest in full on the earlier of the company's 2027 annual stoc", "url": "https://www.stocktitan.net/sec-filings/ANIK/form-4-anika-therapeutics-inc-insider-trading-activity-9f03c92f2277.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:39:32", "published_display": "23 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics increases equity plan shares under amended omnibus and ESPP", "summary": "Anika Therapeutics' board has approved amendments to its 2017 Omnibus Incentive Plan and 2021 Employee Stock Purchase Plan (ESPP), which will increase share reserves, pending stockholder approval at the 2026 Annual Meeting. The 2017 Plan will reserve an additional 350,000 shares,", "url": "https://www.tradingview.com/news/tradingview:9b0dc9415ef36:0-anika-therapeutics-increases-equity-plan-shares-under-amended-omnibus-and-espp/", "source_name": "TradingView", "published_at": "2026-06-23T20:39:31", "published_display": "23 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Anika Therapeutics, Inc. Insider Trading Activity", "summary": "Anika Therapeutics director Sheryl L. Conley reported an acquisition of 10,402 restricted stock units (RSUs) of common stock as an equity award in a Form 4 filing. These RSUs vest fully on the earlier of the company's 2027 annual stockholder meeting or June 18, 2027. Following th", "url": "https://www.stocktitan.net/sec-filings/ANIK/form-4-anika-therapeutics-inc-insider-trading-activity-698a561bccc7.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:39:31", "published_display": "23 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics (NASDAQ: ANIK) shareholders back equity plans and director slate", "summary": "Anika Therapeutics shareholders approved changes to its equity compensation plans and elected three Class III directors at its 2026 Annual Meeting. The approved revisions include increasing the common stock reserved under the omnibus incentive plan by 350,000 shares and doubling ", "url": "https://www.stocktitan.net/sec-filings/ANIK/8-k-anika-therapeutics-inc-reports-material-event-b917cfa932eb.html", "source_name": "Stock Titan", "published_at": "2026-06-23T19:39:31", "published_display": "23 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Anika Therapeutics (NASDAQ: ANIK) receives 10,402 RSU grant", "summary": "Anika Therapeutics director Gary P. Fischetti was granted 10,402 restricted stock units (RSUs), increasing his direct holdings to 52,015 shares. The RSUs, valued at $0.00 per share, encourage long-term alignment with shareholder interests by vesting fully on the earlier of the co", "url": "https://www.stocktitan.net/sec-filings/ANIK/form-4-anika-therapeutics-inc-insider-trading-activity-7f1b19f21bf5.html", "source_name": "Stock Titan", "published_at": "2026-06-21T10:11:24", "published_display": "21 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Inc (ANIK) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Anika Therapeutics Inc (ANIK) currently holds a strong financial score of 7.95, placing it 52nd out of 203 in the Healthcare Equipment & Supplies industry. The company reported a 13.16% year-over-year increase in its latest quarterly revenue, reaching $29.61M, and a net profit in", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anik/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T04:39:54", "published_display": "18 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Inc (ANIK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Anika Therapeutics Inc (ANIK) based on its business segments and geographical regions. As of April 6, 2024, the company's revenue is primarily driven by its OEM Channel (57.09%) and Commercial Channel (42.91%). Geographically", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anik/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:08:57", "published_display": "17 Jun 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Inc (ANIK) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Anika Therapeutics Inc's (ANIK) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and indicates no historical data for stock splits. The page also presents current stock pe", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anik/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T19:08:57", "published_display": "17 Jun 2026 19:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Inc (ANIK) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis of Anika Therapeutics Inc (ANIK), noting its current valuation score of 8.58, ranking it 83 out of 203 in the Healthcare Equipment & Supplies industry. It highlights the company's P/E ratio of -18.06, which is significantly below its rece", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anik/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T10:40:20", "published_display": "17 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Inc (ANIK) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Anika Therapeutics Inc (ANIK), detailing its current price momentum, support and resistance levels, and indicator readings. The analysis covers various technical indicators like MACD, RSI, and moving averages (MA5 to MA200), concludin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anik/technical", "source_name": "TradingKey", "published_at": "2026-06-17T10:40:20", "published_display": "17 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Inc (ANIK) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Anika Therapeutics Inc (ANIK) currently has an earnings forecast score of 9.00, placing it 4th in the Healthcare Equipment & Supplies industry. Analysts have a consensus \"Strong Buy\" rating for ANIK, with an average price target of $16.00. The company's expected revenue for the n", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anik/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T10:40:20", "published_display": "17 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(ANIK) Movement Within Algorithmic Entry Frameworks", "summary": "The article analyzes Anika Therapeutics Inc. (NASDAQ: ANIK) through algorithmic entry frameworks, identifying a strong near-term sentiment with a long-term positive bias. It highlights an exceptional 58.3:1 risk-reward setup targeting a 16.6% gain and provides three institutional", "url": "https://news.stocktradersdaily.com/news_release/10/ANIK_Movement_Within_Algorithmic_Entry_Frameworks_061326061402_1781388842.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-13T18:14:00", "published_display": "13 Jun 2026 18:14", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Griffin Stephen D.", "summary": "This document is a statement of changes in beneficial ownership of securities for Officer Griffin Stephen D. at Anika Therapeutics. It is filed as a Form 4, indicating a mandatory disclosure of transactions by company insiders.", "url": "https://www.moomoo.com/news/notice/307479012/anika-therapeutics-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-13T13:10:18", "published_display": "13 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics (ANIK) Edges Higher as Shares Test Key Resistance Levels - Key Reversal Day", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQVWpfdEQxZmNfdkplaXBjbkkzd0NmQ0dZZjNIdXpBbENMY0daSjFBcU9GaldUZEtLVXBIc1MtSWpneVFrazFjUU1ud1phYTRoc3NxYnVpa3ZudTJqdEstN2cyUnI1Nk8tNEJLU0Q1aW14WjNFbGUxTWdwZU82NzlRNWg4UnJ4S2pkS2FRY1RqRG1iVncteHp0Q0NJeG5SVlY1OEFNX0JmRTFGZHVFNHA3cUl5NUF5S2F2QWI2UmFfcHE?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Anika Therapeutics Inc. announced inducement grants of restricted stock units (RSUs) to a newly hired non-executive employee on June 1, 2026. The grant, covering 3,360 shares, was made under the company's 2021 Inducement Plan and was approved by the compensation committee in acco", "url": "https://finance.yahoo.com/markets/stocks/articles/anika-reports-inducement-grants-under-210000086.html", "source_name": "Market source", "published_at": "2026-06-08T11:40:11", "published_display": "08 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika reports inducement grants", "summary": "Anika Therapeutics, Inc. announced that it granted restricted stock units (RSUs) covering 3,360 shares of common stock to a newly hired non-executive employee on June 1, 2026. This grant was made under the company's 2021 Inducement Plan and was approved by the compensation commit", "url": "https://medicalbuyer.co.in/anika-reports-inducement-grants-3/", "source_name": "Medical Buyer", "published_at": "2026-06-08T11:09:47", "published_display": "08 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics grants 3,360 RSUs to new employee as inducement under Nasdaq rules.", "summary": "Anika Therapeutics has granted 3,360 restricted stock units (RSUs) to a new non-executive employee. This grant, made on June 1, 2026, serves as an inducement for employment under Nasdaq rules and will vest in equal installments over three years, dependent on continuous service. T", "url": "https://pluang.com/en/news-feed/anika-laporkan-pemberian-saham-terbatas-untuk-karyawan-baru", "source_name": "Pluang", "published_at": "2026-06-05T21:09:43", "published_display": "05 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Anika hire receives 3,360 stock units as job inducement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNMzhrMDJuTUUwZHllQkJiZjNWTjdaRHdRLVRPQlUtTEViYXpyVmhYX0Q2YWp6NWtiTGcwN3FDWVdVMU9yVGRsY3V4dXJTTkdaTDIyWlJVZVBCYk9Iamh4WHlRY2FjYVJyb3J4NE4xRzZ4R21YNWJISklEaW4tMDduSlkzemVXWEMwUnVMNFpKbklaNkVub2FQTV9mZTRQcW9VX0RORkNlR1M3VFZrejYzbFlxOUZuUU5sLUs0?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics (ANIK) Hovers Near Support With Minimal Price Movement - Resistance Breakout Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQM1o4SVpvS2hqd251b1p6VklIU1ZBd3BVSjkyamFPTjhsWVhHazUtTXBBbDFPRTBpbVMwNVNleHRGUmhhQzM4WDh0SGJWYjFWSXowX0o0V3lUYkZUNUUxSFYzTFlhUFF0TTh3RWh3OHlOWnlMQWpualczUEN4ZWd1NHowNFhfZGhmeWtnT1hiWHR3WFpHcGlMQ2c0MHh2Wkl2R0RyaS1ZTmhXRi1SeXRFQkFXUnREZEdhYi1n?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "President of Anika Therapeutics Picks Up 51% More Stock", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/president-anika-therapeutics-picks-51-133628327.html", "source_name": "Simply Wall St.", "published_at": "2026-05-03T13:36:28+00:00", "published_display": "03 May 2026 13:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics (ANIK) Q4 Profit Challenges Ongoing Unprofitability Narrative Ahead Of Q1 Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bullish On Anika Therapeutics\u2019s Pullback As Integrity Scales (NASDAQ:ANIK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQUkJOUk5JaTUtcjZ4SUdYY0tONDkxMUU2QVVUNnhmVE5nTC03enpCbnd5QURuVVpQREZRUzVGQ0xQbVRJdHZBeU1XMVlsOThaNVlNV1FId3lBN0c3VDVMeXRPSi1XZjlUQzNmQXV1YW9qdDFXbnNab1F5YzI5TkM2UDFWNG5FdVhWYjF1bHYtcXhTUC1wSUttWVFESkpwcWtjemc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/58d88200-1129-3efb-806a-65aac008518e/anika-therapeutics-q1.html", "source_name": "MarketBeat", "published_at": "2026-04-29T14:20:26+00:00", "published_display": "29 Apr 2026 14:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/anika-q1-earnings-snapshot-111451597.html", "source_name": "Associated Press", "published_at": "2026-04-29T11:14:51+00:00", "published_display": "29 Apr 2026 11:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/anika-reports-first-quarter-2026-110500399.html", "source_name": "GlobeNewswire", "published_at": "2026-04-29T11:05:00+00:00", "published_display": "29 Apr 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPeU5mR250NHZjRnFZT3pGaGc4eTN3SGRZUnpPeFFMM3B5cWVSa29WQnRyMFMtS1FLVXAzV0FKeUFsQ05NX0Nnbkswbjk5V2ZRNTQ4ZU14R1Q5bF9XaVJubER4OFpPQmpzRGNzclQ3MjVaS0tJenJIcWdoTVd4ZENtbXNOMFZpQUs3dWNWdjdyZUdwdU1uM2tRTVVJUW9lWE5S?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOeElqTzdGRGVmTUxTYmlueVl6MmM2eE5WUU44OHdsMUozekJzNDdCWGxlUnBQZ2JNYVhuTl91T3RjbHBLQWZST1M5YTctUUZDQzhKd0JnWHBvWE83b2dzZS1peHNzc1didDFZcmIzdDNFSDU4N3V4dVpYLUZJRnBGQTU3LTlQb2MtT0dZSzkwZ05ocTBzMTFmOFBORGdNSjZYS2Q1eVJqcHRhNGNCXzY0OTZnb01lb0pIeUlITXVvaWt3Z2tJd0JWUVF4YUNYRkNUYnZDUWRJNHUtRm9XeUZ1RGxKa04?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Anika employee gets 3,138 stock units vesting over 3 years", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQcVp2OXRXVHdYMk54dUNpU21JRGY3M2R3dzlIUU53ZllWcXpHNjRkdnVuNUdxWkpuLUF6R0lLLTZyZlUwdUpYR09SemIxMXpKX2tYWkE3N0FjUVFUZnJ0X0lpME1PYi1sTmtBdlAwdnA2NUh4NDRJZDVVaHV6WUNIN2RHcHRKWXVvbFpzaUxZbXNfM2RaUFNhQnFKZHk1cGxqU1ozcmlSQTk4YnBaYzZCdkpycmZ4SDhpZmw4?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANIKA THERAPEUTICS ($ANIK) Releases Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPRXpLY21sSWx5b2t2b09HYllxWXM2cnVlZnlwX2Q1NFU0U1RMT2kxWE1iQ3pBcHdrR3dtakZ2cWZTejlKdnUxOWhlcDFERkxLY3ZlSmtabm9ZUHA1THVMcFhNV3pBWERrdFcwVDlGTHdfdTZVVUtwWHlsQ1VFanVlU2JoV09rUl9GUzJjQzln?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C.", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-01-26T08:00:00+00:00", "published_display": "26 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Osteoarthritis Therapeutics Market Size, Share | Growth [2034]", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQTGhscWV3bkFLYUFRZEJlV28wSEY2SlRCNVlZWlVHMTZXTzBaUEh0QUFhaEJRWkp5bGU5WGZ2cVduRG96MFpZWDM5V184ejlxZjlTRUVvZHpVZndraUd3NHFwV0FuYXRUQTBwd2hHUnIyU3hDVFUyOFVNVUVLNEFGSU5oRE9UX3lP?oc=5", "source_name": "Fortune Business Insights", "published_at": "2026-01-21T09:41:42+00:00", "published_display": "21 Jan 2026 09:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anika Therapeutics (ANIK) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5MNUpteXpnQ2QyOE1qYTh1MEVDUU5WYlJLZ0JXS3JWUm1QbXVOeFFrcVVlOWNIS1VtRE5HU0FiSGNQd1V4YXhuRjRSWjNjUmVxZFNZ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:25:10+00:00", "published_display": "25 Apr 2025 00:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 85, "total_relevant": 46, "sentiment_summary": {"positive": 12, "negative": 2, "neutral": 32, "score": 54, "total": 46, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 11.9, "count": 21}, {"event": "earnings", "label": "Earnings", "weight": 9.15, "count": 16}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 15.6, "latest_week": "2026-07-10", "one_week_move": 1.6, "four_week_move": 6.0, "twelve_week_move": -2.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.476876, "market_dynamics_buy_signal": false, "relative_strength": 16.844535, "fair_value_gap": -10.7, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 48.5037, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.6% over one week, +6.0% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 10}, {"label": "TradingView", "count": 6}, {"label": "TradingKey", "count": 6}, {"label": "GlobeNewswire", "count": 4}, {"label": "Donan\u0131mHaber", "count": 3}, {"label": "Market source", "count": 2}, {"label": "scanx.trade", "count": 1}, {"label": "TipRanks", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 21}, {"label": "Earnings", "count": 16}, {"label": "Balance sheet", "count": 5}, {"label": "Regulatory and legal", "count": 2}, {"label": "Deals and strategy", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+1.6% over one week, +6.0% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Anika Therapeutics to issue Q2FY26 results on July 29"}], "updated_at": "2026-07-16T09:44:07.753005+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}